ENSIKLOPEDIA Cari Tekan Enter untuk memulai pencarian cepat. Kembali ke Ensiklopedia Arsip Wikipedia Indonesia NITD008 NITD008Chemical compound Pharmaceutical compoundNITD008Clinical dataTrade namesNITD008Identifiers IUPAC name (2R,3R,4R,5R)-2-(4-Amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-3-ethynyl-5-(hydroxymethyl)tetrahydrofuran-3,4-diol CAS Number1044589-82-3 YPubChem CID44633776ChemSpider26376187UNIILKI7T3WQ2EChEMBLChEMBL1630221CompTox Dashboard (EPA)DTXSID701159354 Chemical and physical dataFormulaC13H14N4O4Molar mass290.279 g·mol−13D model (JSmol)Interactive image SMILES C#C[C@]1([C@@H]([C@H](O[C@H]1N2C=CC3=C2N=CN=C3N)CO)O)O InChI InChI=1S/C13H14N4O4/c1-2-13(20)9(19)8(5-18)21-12(13)17-4-3-7-10(14)15-6-16-11(7)17/h1,3-4,6,8-9,12,18-20H,5H2,(H2,14,15,16)/t8-,9-,12-,13-/m1/s1Key:NKRAIOQPSBRMOV-NRMKKVEVSA-N NITD008 is an antiviral drug classified as an adenosine analog (a type of nucleoside analog). It was developed as a potential treatment for flavivirus infections and shows broad spectrum antiviral activity against many related viruses such as dengue virus, West Nile virus, yellow fever virus, Powassan virus, hepatitis C virus, Kyasanur Forest disease virus, Omsk hemorrhagic fever virus, and Zika virus.[1][2][3] However, NITD008 proved too toxic in pre-clinical animal testing to be suitable for human trials, but it continues to be used in research to find improved treatments for emerging viral diseases.[4] See also Favipiravir, a drug approved by China, Germany, Indonesia, Iran, Japan, Thailand, and Turkey for treating COVID-19 patients MK-608, a drug with a similar structure Remdesivir, FDA approved antiviral drug with a similar structure Ribavirin, another antiviral drug with teratogenic side effects that was patented by Merck in 1971 and approved by the FDA in 1986 References ↑ Yin Z, Chen YL, Schul W, Wang QY, Gu F, Duraiswamy J, et al. (December 2009). "An adenosine nucleoside inhibitor of dengue virus". Proceedings of the National Academy of Sciences of the United States of America. 106 (48): 20435–9. Bibcode:2009PNAS..10620435Y. doi:10.1073/pnas.0907010106. PMC 2787148. PMID 19918064. ↑ Lo MK, Shi PY, Chen YL, Flint M, Spiropoulou CF (June 2016). "In vitro antiviral activity of adenosine analog NITD008 against tick-borne flaviviruses". Antiviral Research. 130: 46–9. doi:10.1016/j.antiviral.2016.03.013. PMC 5096641. PMID 27016316. ↑ Deng YQ, Zhang NN, Li CF, Tian M, Hao JN, Xie XP, et al. (October 2016). "Adenosine Analog NITD008 Is a Potent Inhibitor of Zika Virus". Open Forum Infectious Diseases. 3 (4) ofw175. doi:10.1093/ofid/ofw175. PMC 5063548. PMID 27747251. ↑ Nelson J, Roe K, Orillo B, Shi PY, Verma S (October 2015). "Combined treatment of adenosine nucleoside inhibitor NITD008 and histone deacetylase inhibitor vorinostat represents an immunotherapy strategy to ameliorate West Nile virus infection". Antiviral Research. 122: 39–45. doi:10.1016/j.antiviral.2015.07.008. PMC 4853296. PMID 26225754. vteRNA virus antivirals (primarily J05, also S01AD and D06BB)Hepatitis CNS3/4A protease inhibitors (–previr) Asunaprevir Boceprevir‡ Ciluprevir§ Danoprevir† Faldaprevir‡ Glecaprevir Grazoprevir Narlaprevir Paritaprevir Simeprevir Sovaprevir† Telaprevir‡ Vaniprevir Vedroprevir§ Voxilaprevir NS5A inhibitors (–asvir) Coblopasvir Daclatasvir# Elbasvir Ledipasvir Netanasvir Odalasvir† Ombitasvir Pibrentasvir Ravidasvir† Ruzasvir† Samatasvir† Velpatasvir NS5B RNA polymerase inhibitors (–buvir) Beclabuvir† Bemnifosbuvir† Dasabuvir# Deleobuvir§ Encofosbuvir Filibuvir§ GS-6620§ IDX-184§ Setrobuvir§ Sofosbuvir# Tegobuvir§ TMC-647055§ Radalbuvir† Uprifosbuvir† Combination drugs Elbasvir/grazoprevir Glecaprevir/pibrentasvir Ledipasvir/sofosbuvir# Ombitasvir/paritaprevir/ritonavir# Sofosbuvir/daclatasvir Sofosbuvir/velpatasvir# Sofosbuvir/velpatasvir/voxilaprevir Hepatitis D Bulevirtide Picornavirus viral entry: Pleconaril† Anti-influenza agents Baloxavir marboxil Onradivir Pimodivir† Umifenovir adamantane derivatives/M2 inhibitors (Adapromine Amantadine Rimantadine) neuraminidase inhibitors/release phase (Oseltamivir# Zanamivir Peramivir, Laninamivir†) Multiple/generalInterferon Interferon alfa 2b Peginterferon alfa-2a# Peginterferon alfa-2b# 3CL protease inhibitors (–trelvir) Atilotrelvir Ensitrelvir† Ibuzatrelvir Leritrelvir Lufotrelvir Nirmatrelvir† (+ritonavir)† Rupintrivir Simnotrelvir (+ritonavir†) RNA pol inhibitors CMX521§ Deuremidevir† Favipiravir Galidesivir† GS-441524§ Remdesivir MK-608§ Mericitabine† Molnupiravir NITD008§ Ribavirin# Taribavirin† Triazavirin Valopicitabine† Multiple/Unknown/Other EICAR§ Merimepodib§ Moroxydine Presatovir† #WHO-EM ‡Withdrawn from market Clinical trials: †Phase III §Never to phase III
